Tenaya Therapeutics has appointed Tim Hoey chief scientific officer of the South San Francisco, CA, biotech. Before joining Tenaya, Hoey was senior vice president of cancer biology and co-chief scientific officer of Redwood City, CA-based OncoMed (NASDAQ: [[ticker:OMED]]). Tenaya spun out of the Gladstone Institutes last year backed by a $50 million Series A investment that the startup is using to develop regenerative medicine treatments for heart failure.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
